Health and economic outcomes over 20 years with 4th-generation immunoassay.

All outcomes are relative to the status quo (approximately 1.18 million new infections over 20 years). MSM = men who have sex with men; IDU = injection drug user; 4G assay = fourth-generation antigen-antibody combination assay; AHI = acute HIV infection; NAAT = nucleic acid amplification test; QALY = quality-adjusted life year; ICER = incremental cost-effectiveness ratio compared to the status quo or next best strategy for each risk group. * = weakly dominated strategy (this strategy is not on the cost-effectiveness frontier and is thus not economically efficient).